

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 475 411 B1

(12)

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:

13.06.2001 Bulletin 2001/24

(21) Application number: 91115485.4

(51) Int Cl.7: C07D 473/00, C07D 473/34,  
C07D 487/04, C07D 471/04,  
A61K 31/52, A61K 31/435,  
A61K 31/44, A61K 31/505

(22) Date of filing: 12.09.1991

### (54) Novel carbocyclic adenosine analogs useful as immunosuppressants

Neue als Immunsuppressiva nützliche karbozyklische Adenosinanaloge

Analogues carbocycliques nouveaux d'adénosine utiles comme immunosupresseurs

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: 14.09.1990 US 582280

23.08.1991 US 748172

(43) Date of publication of application:

18.03.1992 Bulletin 1992/12

(73) Proprietor: Aventis Pharmaceuticals Inc.

Bridgewater, NJ 08807-0800 (US)

(72) Inventors:

- Borchering, David R.  
Overland Park Kansas 66213 (US)
- Edwards III, Carl K.  
Olathe, Kansas 66062 (US)
- Esser, Ronald E.  
Kansas City, Missouri 64113 (US)
- Cole, Douglas L.  
Stanley, Kansas 66224 (US)

(74) Representative: VOSSIUS & PARTNER

Postfach 86 07 67  
81634 München (DE)

(56) References cited:

EP-A- 0 236 935	EP-A- 0 291 229
EP-A- 0 291 917	EP-A- 0 368 640
DE-A- 2 714 263	US-A- 3 682 918
US-A- 3 917 837	US-A- 4 221 794
US-A- 4 386 093	US-A- 4 859 677

- CHEMICAL ABSTRACTS, vol. 62, April 12-May 10 1965, Columbus, Ohio, USA H.J. SCHAEFFER et al. "Enzyme Inhibitors. I. Inhibition of adenosine deaminase by Isosteric nucleosides" abstract-no. 9 130f
- CANCER RES. vol. 32, 1962, page 329
- MED. RES. REV. vol. 6, 1986, page 1
- DRUGS FUT. vol. 13, 1988, page 653
- ANN.N.Y.ACAD.SCI. 1975, page 412
- DEV.PHARMACOL. vol. 2, 1983, page 249

EP 0 475 411 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

[0001] This invention relates to certain carbocyclic adenosine analogs which are useful as immunosuppressants.

[0002] Immunity is concerned with the recognition and disposal of foreign antigenic material which is present in the body. Typically the antigens are in the form of particulate matter (i.e., cells, bacteria, etc.) or large protein or polysaccharide molecules which are recognized by the immune system as being "non-self", i.e., detectably different or foreign from the animal's own constituents. Potential antigens can be a variety of substances, often proteins, which are most frequently located on the outer surfaces of cells. For example, potential antigens can be found on pollen grains, tissue grafts, animal parasites, viruses, and bacteria. Once the antigenic material is recognized as "non-self" by the immune system, natural (non-specific) and/or adaptive immune responses can be initiated and maintained by the action of specific immune cells, antibodies and the complement system. Under certain conditions, including in certain disease states, an animal's immune system will recognize its own constituents as "non-self" and initiate an immune response against "self" material.

[0003] An immune response can be carried out by the immune system by means of natural or adaptive mechanisms, each of which are composed of both cell-mediated and humoral elements. Natural mechanisms for immune response refer to those mechanisms involved in essentially non-specific immune reactions which involve the complement system and myeloid cells alone, such as macrophages, mast cells and polymorphonuclear leukocytes (PMN), in reacting to certain bacteria, viruses, tissue damage and other antigens. These natural mechanisms provide what is referred to as natural immunity. Adaptive mechanisms for immune response refer to those mechanisms which are mediated by lymphocytes (T and B cells) and antibodies which can respond selectively to thousands of different materials recognized as "non-self". These adaptive mechanisms provide what is referred to as adaptive immunity and lead to a specific memory and a permanently altered pattern of response in adaptation to the animal's own environment. Adaptive immunity can be provided by the lymphocytes and antibodies alone or, more commonly, can be provided by the interaction of lymphocytes and antibodies with the complement system and myeloid cells of the natural mechanisms of immunity.

[0004] The antibodies provide the humoral element of the adaptive immune response and the T-cells provide the cell-mediated element of the adaptive immune response.

[0005] Natural mechanisms of immune response involve phagocytosis by macrophages and PMN whereby foreign material or antigen is engulfed and disposed of by these cells. In addition, macrophages can kill some foreign cells through their cytotoxic effects. The complement system which is also involved in natural immunity is made up of various peptides and enzymes which can attach to foreign material or antigen and thereby promote phagocytosis by macrophages and PMN, or enable cell lysis or inflammatory effects to take place.

[0006] Adaptive mechanisms of immune response involve the actions against specific antigens of antibody secreted by B-lymphocytes (or B-cells) as well as the actions of various T-lymphocytes (or T-cells) on a specific antigen, on B-cells, on other T-cells and on macrophages.

[0007] Antibodies, which are responsible for the humoral aspect of adaptive immunity, are serum globulins secreted by B-cells with a wide range of specificity for different antigens. Antibodies are secreted in response to the recognition of specific antigens and provide a variety of protective responses. Antibodies can bind to and neutralize bacterial toxins and can bind to the surface of viruses, bacteria, or other cells recognized as "non-self" and thus promote phagocytosis by PMN and macrophages. In addition, antibodies can activate the complement system which further augments the immune response against the specific antigen.

[0008] Lymphocytes are small cells found in the blood which circulate from the blood, through the tissues, and back to the blood via the lymph system. There are two major subpopulations of lymphocytes called B-cells and T-cells. B-cells and T-cells are both derived from the same lymphoid stem cell with the B-cells differentiating in the bone marrow and the T-cells differentiating in the thymus. The lymphocytes possess certain restricted receptors which permit each cell to respond to a specific antigen. This provides the basis for the specificity of the adaptive immune response. In addition, lymphocytes have a relatively long lifespan and have the ability to proliferate clonally upon receiving the proper signal. This property provides the basis for the memory aspect of the adaptive immune response.

[0009] B-cells are the lymphocytes responsible for the humoral aspect of adaptive immunity. In response to recognition of a specific foreign antigen, a B-cell will secrete a specific antibody which binds to that specific antigen. The antibody neutralizes the antigen, in the case of toxins, or promotes phagocytosis, in the case of other antigens. Antibodies also are involved in the activation of the complement system which further escalates the immune response toward the invading antigen.

[0010] T-cells are the lymphocytes responsible for the cell-mediated aspect of adaptive immunity. There are three major types of T-cells, i.e., the Cytotoxic T-cells, Helper T-cells and the Suppressor T-cells. The Cytotoxic T-cells detect and destroys cells infected with a specific virus antigen. Helper T-cells have a variety of regulatory functions. Helper T-cells, upon identification of a specific antigen, can promote or enhance an antibody response to the antigen by the appropriate B-cell and can promote or enhance phagocytosis of the antigen by macrophages. Suppressor T-cells have the effect of suppressing an immune response directed toward a particular antigen.

[0010] The cell-mediated immune response is controlled and monitored by the T-cells through a variety of regulatory messenger compounds secreted by the myeloid cells and the lymphocyte cells. Through the secretion of these regulatory messenger compounds, the T-cells can regulate the proliferation and activation of other immune cells such as B-cells, macrophages, PMN and other T-cells. For example, upon binding a foreign antigen, a macrophage or other antigen presenting cell can secrete interleukin-1 (IL-1) which activates the Helper T-cells. T-cells in turn secrete certain lymphokines, including interleukin-2 (IL-2) and  $\gamma$ -interferon, each of which have a variety of regulatory effects in the cell-mediated immune response. Lymphokines are a large family of molecules produced by T-cells (and sometimes B-cells) including

- 10 IL-2, which promotes the clonal proliferation of T-cells;
- MAF or macrophage activation factor, which increases many macrophage functions including phagocytosis, intracellular killing and secretion of various cytotoxic factors;
- NAF or neutrophil activation factor, which increases many functions of the PMN including phagocytosis, oxygen radical production, bacterial killing, enhanced chemotaxis and enhanced cytokine production;
- 15 MIF or macrophage migration factor, which by restricting the movement of macrophages, concentrates them in the vicinity of the T-cell;
- $\gamma$ -interferon, which is produced by the activated T-cell and is capable of producing a wide range of effects on many cells including inhibition of virus replication, induction of expression of class II histocompatibility molecules allowing these cells to become active in antigen binding and presentation, activation of macrophages, inhibition of cell growth, induction of differentiation of a number of myeloid cell lines.

20 [0011] Activated macrophages and PMNs, which provide an enhanced immune response as part of the cell-mediated adaptive immunity, are characterized as having increased production of reactive oxygen intermediates. This increased production of reactive oxygen intermediates, or respiratory burst, is known as "priming". Certain lymphokines, such as 25  $\gamma$ -interferon, trigger this respiratory burst of reactive oxygen intermediates in macrophages and PMNs. Thus, lymphokines, such as  $\gamma$ -interferon, which are secreted by the T-cells provide an activation of these macrophages and PMNs which results in an enhanced cell-mediated immune response.

30 [0012] The immune response can provide an immediate or a delayed type of response. Delayed-type hypersensitivity is an inflammatory reaction which occurs in immune reactive patients within 24-48 hours after challenge with antigen and is the result primarily of a cell-mediated immune response. In contrast, immediate-type hypersensitivity, such as 35 that seen in anaphylactic or Arthus reactions, is an inflammatory reaction which occurs in immune reactive patients within minutes to a few hours after challenge with antigen and is the result primarily of humoral or antibody-mediated immune response.

40 [0013] The ability of the immune system, and in particular the cell-mediated immune system, to discriminate between "self" and "non-self" antigens is vital to the functioning of the immune system as a specific defense against invading microorganisms. "Non-self" antigens are those antigens on substances in the body which are detectably different or foreign from the animals own constituents and "self" antigens are those antigens which are not detectably different or foreign from the animals own constituents. Although the immune response is a major defense against foreign substances which can cause disease, it cannot distinguish between helpful and harmful foreign substances and destroys both.

45 [0014] There are certain situations, such as with an allogeneic transplant or in "graft versus host" disease, where it would be extremely useful to suppress the immune response in order to prevent the rejection of helpful foreign tissue or organs. Allogeneic tissues and organs are tissues and organs from a genetically different member of the same species. "Graft versus host" disease occurs where the transplanted tissue, for example in a bone marrow transplant, contains allogeneic T-cells of the donor which cause an immune response against the recipient's own tissues. Although both humoral and cell-mediated immune responses play a role in the rejection of allogeneic tissues and organs, the primary mechanism involved is the cell-mediated immune response. Suppression of the immune response, and in particular, suppression of cell-mediated immune response, would thus be useful in preventing such rejection of allograft tissues and organs. For example, cyclosporin A is currently used as an immunosuppressive agent in the treatment of 50 patients receiving allogeneic transplants and in "graft versus host" disease.

55 [0015] There are times when the individual's immunological response causes more damage or discomfort than the invading microbes or foreign material, as in the case of allergic reactions. Suppression of the immune response in these cases would be desirable.

[0016] Occasionally, the immunological mechanisms become sensitized to some part of the individual's own body causing interference with or even destruction of that part. The ability to distinguish between "self" and "non self" is impaired and the body begins to destroy itself. This can result in an autoimmune diseases such as rheumatoid arthritis, insulin-dependent diabetes mellitus (which involves the autoimmune destruction of the  $\beta$ -cells of the islets of Langerhans which are responsible for the secretion of insulin), certain hemolytic anemias, rheumatic fever, thyroiditis, ulcer-

active colitis, myasthenia gravis, glomerulonephritis, allergic encephalo-myelitis, continuing nerve and liver destruction which sometimes follows viral hepatitis, multiple sclerosis and systemic lupus erythematosus. Some forms of autoimmunity come about as the result of trauma to an area usually not exposed to lymphocytes such as neural tissue or the lens of the eye. When the tissues in these areas become exposed to lymphocytes, their surface proteins can act as 5 antigens and trigger the production of antibodies and cellular immune responses which then begin to destroy those tissues. Other autoimmune diseases develop after exposure of the individual to antigens which are antigenically similar to, that is cross-react with, the individual's own tissue. Rheumatic fever is an example of this type of disease in which the antigen of the streptococcal bacterium which causes rheumatic fever is cross-reactive with parts of the human heart. The antibodies cannot differentiate between the bacterial antigens and the heart muscle antigens and cells with 10 either of those antigens can be destroyed. Suppression of the immune system in these autoimmune diseases would be useful in minimizing or eliminating the effects of the disease. Certain of these autoimmune diseases, for example, insulin-dependent diabetes mellitus, multiple sclerosis and rheumatoid arthritis, are characterized as being the result of a cell-mediated autoimmune response and appear to be due to the action of T-cells [See Sinha et al. *Science* 248, 1380 (1990)]. Others, such as myasthenia gravis and systemic lupus erythematosus, are characterized as being the 15 result of a humoral autoimmune response [*Id.*].

[0017] Suppression of the immune response would thus be useful in the treatment of patients suffering from autoimmune diseases. More particularly, suppression of cell-mediated immune response would thus be useful in the treatment of patients suffering from autoimmune diseases due to the action of T-cells such as insulin-dependent diabetes mellitus, multiple sclerosis and rheumatoid arthritis. Suppression of humoral immune response would be useful in the treatment 20 of patients suffering from T-cell independent autoimmune diseases such as myasthenia gravis and systemic lupus erythematosus.

In DE-A 27 14 263 triazopyrimidine derivatives are disclosed for the topical treatment of psoriasis. C.A. 62 9. 103 f (1964) and J. Pharm. Sci. 53, 1368 (1964) pertain to cis- and trans-2-hydroxy cyclopentane derivatives which are useful as inhibitors of adenosine deaminase.

25 US-A-39 17 837 discloses trans-2(6-amino-9H-purin-9yl) glycopentanol which is useful as an anti-inflammatory agent. In US-A-48 59 677 anti-viral nucleoside analogues with a dihydroxy cyclopentene substituent are disclosed. US-A-48 36 093 pertains to a 4-hydroxymethyl-2,3-dihydroxy cyclopentane which is useful as an antiviral agent and an inhibitor of S-adenoylcysteine hydrolase.

[0018] In EP-A-0 236 935 purine nucleosides substituted with hydroxymethyl cyclopentane are disclosed to be useful 30 as antiviral agents especially in inhibiting the growth of the AIDS virus.

EP-A-0 291 229 pertains to hydroxymethyl guanines which show thymidine kinase inhibiting activity. In EP-A-0 368 640 dihydroxy cyclopentyl purines are disclosed for the treatment and/or prophylaxis of parasitic infections.

Cancer Res. 22,329 (1962) relates to a number of 9-alkylpurines (e.g. cyclopentyl and cis-/trans-2-hydroxycyclopentyl derivatives) which are said to have antiviral activities.


35 Med. Res. Rev. 6,1 (1986) discloses antitumor and antiviral agents having a hydroxymethyl or hydroxymethyl-(di) hydroxy group at the cyclopentyl ring of the purine analogues.

Drugs Future 13, 653 (1988) discloses the potential use of purine nucleoside phosphorylase (PNP) inhibitors as selective immunosuppressants.

40 In Ann. N.Y. Acad. Sci. 412 (1975) the biological enzymatic conversion of purine analogues is discussed. Dev. Pharmacol. 2, 249 (1983) discusses the involvement of adenosine and cyclic nucleotides in modulating the immune response.

EP-A-0 291 917 pertains to ribose analogues (oxetanocines) which have immunosuppressive and antiviral activities. Finally, US-A-42 21 794 discloses the immunomodulating and antiviral activity of certain purine analogues.

45 [0019] The present invention provides novel compounds of the formula (1)



15 wherein

the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,  
Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> and Y<sub>9</sub> are each independently nitrogen or a CH group.

20 Q is NH<sub>2</sub>, halogen or hydrogen, and  
Z is hydrogen, halogen, or NH<sub>2</sub>;

or a pharmaceutically-acceptable salt thereof.

[0020] The present invention also provides pharmaceutical compositions useful in effecting immunosuppression, and more specifically, in suppressing adaptive immunity, comprising an effective immunosuppressive amount of a compound of formula (1).

[0021] The pharmaceutical compositions comprise an effective immunosuppressive amount of a compound of formula (1) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

[0022] As used herein the term "halogen" refers to monovalent iodine, bromine, chlorine or fluorine radicals, the term "nitrogen" refers to a trivalent nitrogen radical and the term "CH group" refers to a methylidyne radical.

[0023] As used herein, the term "pharmaceutically-acceptable salts" refers to acid addition salts of the compounds of formula (1) wherein the toxicity of the compound is not increased compared to the non-salt. Representative examples of pharmaceutically-acceptable salts, which are made by treating the compounds of formula (1) with the corresponding acids, are: hydrobromide, hydrochloride, sulfuric, phosphoric, nitric, formic, acetic, propionic, succinic, glycolic, lactic, malic, tartaric, citric, ascorbic,  $\alpha$ -ketoglutaric, glutamic, aspartic, maleic, hydroxymaleic, pyruvic, phenylacetic, benzoic, paraaminobenzoic, anthranilic, para-hydroxybenzoic, salicylic, para-aminosalicylic, methanesulfonic, ethanesulfonic, hydroxyethanesulfonic, ethylenesulfonic, halobenzenesulfonic, toluenesulfonic, naphthalenesulfonic and sulfanilic acids. The hydrochloride is preferred as the pharmaceutically-acceptable salt of compounds of formula (1).


[0024] It is understood that the hydroxy substituent on the cyclopentanyl ring of the compounds of formula (1) have a CIS configuration relative to the bicyclic substituent. It is further understood that these compounds of formula (1) may exist in a variety of stereoisomeric configurations. Of course, the compounds of formula (1) encompass and include both the individual stereoisomers and racemic mixtures thereof.

[0025] A general synthetic procedure for preparing compounds of formula (1) wherein Y<sub>9</sub> is nitrogen is set forth in Scheme A.

45

50

55



B = Blocking group; L = Leaving group

[0026] In step a, the reactive 4-hydroxy moiety of (1*R*, 4*S*)-Cis-1-acetoxy-2-cyclopenten-4-ol (2) is blocked with a hydroxy protecting group (B) to form the corresponding 4-hydroxy-blocked (1*R*, 4*S*)-Cis-1-acetoxy-2-cyclopenten-4-ol (3). The particular hydroxy protecting group used can be one of many conventional hydroxy protecting groups which are well known and appreciated in the art. The selection and utilization of particular blocking groups are well known to one of ordinary skill in the art. In general, blocking groups should be selected which adequately protect the hydroxy group during subsequent synthetic steps and which are readily removable under conditions which will not cause degradation of the desired product.

[0027] Representative examples of suitable hydroxy blocking groups are tetrahydropyranyl, methoxymethyl, t-butyldimethylsilyl, methoxyethoxy-methyl, acetoxy and the like. The preferred blocking group for the 4-hydroxy moiety of (2)

is a 2-tetrahydropyranyl group. Where it is desired to block the 4-hydroxy of (2) with a 2-tetrahydropyranyl group, (2) can be reacted with 3,4-dihydro-2H-pyran in the presence of trifluoroacetic acid to yield the corresponding (1R,4S)-Cis-1-acetoxy-4-(2-tetrahydropyranloxy)-2-cyclopentene.

[0028] In step b, the 1-acetoxy group of the 4-hydroxy-blocked (1R, 4S)-Cis-1-acetoxy-2-cyclopenten-4-ol (3) is hydrolyzed and the resulting 1-hydroxy is derivatized with a suitable leaving group (L) to form the corresponding 2-cyclopentene derivative (4). The 1-acetoxy group of (3) is first hydrolyzed with a base such as potassium hydroxide, sodium hydroxide or ammonium hydroxide in methanol or ethanol. The 1-hydroxy group of the hydrolyzed derivative thus formed is then derivatized with a leaving group (L). The particular leaving group used can be one of many conventional leaving groups which are well known and appreciated in the art. The selection and utilization of particular leaving groups are well known to one of ordinary skill in the art. In general, a leaving group should be selected which adequately facilitates the displacement of the leaving group by an appropriate nucleoside base derivative to obtain a product with retention of configuration. Representative examples of suitable leaving groups are triflate, brosyl, tosyl, methanesulfonyl and the like. The preferred leaving group for step b is a methanesulfonyl group.

[0029] For example, where it is desired to convert the 4-hydroxy-blocked (1R, 4S)-Cis-1-acetoxy-2-cyclopenten-4-ol (3) to the corresponding 4-hydroxy-blocked (1R, 4S)-Cis-1-methanesulfonyloxy-2-cyclopenten-4-ol, (3) can be hydrolyzed with KOH in ethanol and the resulting free alcohol can then be isolated and converted to the corresponding 4-hydroxy-blocked (1R, 4S)-Cis-1-methanesulfonyloxy-2-cyclopenten-4-ol (4) by treatment with methanesulfonyl chloride in the presence of triethylamine.

[0030] In step c, the 2-cyclopentene derivative (4) bearing a leaving group in the 1-position and a blocked hydroxy group in the 4-position, is subjected to a displacement by the desired nucleoside base (wherein  $Y_9$  is nitrogen) to give the corresponding 3-hydroxy blocked carbocyclic nucleoside analog (5) with retention of configuration. For example, where it is desired to convert a 4-hydroxy-blocked (1R, 4S)-Cis-1-methanesulfonyloxy-2-cyclopenten-4-ol to the corresponding 3-hydroxy-blocked (1R,3S)-Cis-1-(9-adenyl)-4-cyclopenten-3-ol, the methanesulfonyloxy derivative can be treated with adenine in the presence of sodium hydride.

[0031] In step d, the 3-hydroxy blocked carbocyclic nucleoside analog (5) is de-blocked according to standard procedures and techniques well known and appreciated in the art to give the corresponding carbocyclic nucleoside analog (6). For example, where the 3-hydroxy is blocked with a 2-tetrahydropyranyl group, the 3-hydroxy blocking group can be removed by treatment with acid, such as hydrochloric acid.

[0032] In step e, the carbocyclic nucleoside analog (6) is converted to the corresponding carbocyclic adenosine analog (1a) by catalytic hydrogenation, such as by treatment with hydrogen in the presence of  $PtO_2$ .

[0033] Alternatively, compounds of formula (1) wherein  $Y_9$  is nitrogen can be prepared according to the following shortened version of Scheme A. The reactive 4-hydroxy moiety of (1S,4R)-Cis-1-acetoxy-2-cyclopenten-4-ol can be derivatized with a suitable leaving group (L) as described for step b of Scheme A. The most preferred leaving group for this alternative scheme is a mesylate group. The thus formed 2-cyclopentene derivative bearing an acetoxy group in the 1-position and a leaving group such as a mesylate group in the 4-position is then subjected to a displacement by the desired nucleoside base (wherein  $Y_9$  is nitrogen) to give the corresponding 3-hydroxy blocked carbocyclic nucleoside analog (5) as described for step c of Scheme A. The compounds of formula (1) wherein  $Y_9$  is nitrogen are then prepared according to steps d and e of Scheme A.

[0034] The following example presents a typical synthesis as described by Scheme A. This example is understood to be illustrative only and is not intended to limit the scope of the invention in any way. As used herein, the following terms have the indicated meanings: "g" refers to grams; "mmol" refers to millimoles; "mL" refers to milliliters; "DMF" refers to dimethylformamide; " $^{\circ}C$ " refers to degrees Celsius; "mg" refers to milligrams; "N" refers to the normality of a solution; 1 bar =  $10^5$  Pa, "THF" refers to tetrahydrofuran.

#### 45 EXAMPLE 1

##### (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentane hydrochloride

##### Step a: (1R,4S)-Cis-1-acetoxy-4-(2-tetrahydropyranloxy)-2-cyclopentene

[0035] To a stirring solution of (1R,4S)-Cis-1-acetoxy-2-cyclopenten-4-ol (1g, 7.0mmol) in 20 mL of dichloromethane add 3,4-dihydro-2H-pyran (0.6g, 7.1mmol) and 5 drops of trifluoroacetic acid. Stir the mixture for 24 hours. Dilute the mixture with 50mL of dichloromethane and extract with saturated sodium bicarbonate and then brine. Dry the organic layer over sodium sulfate. Remove the solvent under vacuum to yield the title compound (1.58g).

##### Step b: (1R,4S)-Cis-1-methanesulfonyloxy-4-(2-tetrahydropyranloxy)-2-cyclopentene

[0036] Dissolve (1R,4S)-Cis-1-acetoxy-4-(2-tetrahydropyranloxy)-2-cyclopentene (3.0g, 13mmol) in 50mL of abso-

lute ethanol. To this solution add potassium hydroxide (0.8g, 14mmol) and allow the mixture to stir for 3 hours. Concentrate the mixture and apply to a silica gel column (10g) eluting with ethyl acetate/hexane (1:1). Remove the solvent to yield (1R,4S)-Cis-4-(2-tetrahydropyranloxy)-2-cyclopenten-1-ol as a colorless oil (2.38g).

5 Dissolve (1R,4S)-Cis-4-(2-tetrahydropyranloxy)-2-cyclopenten-1-ol (1.2g, 6.6mmol) in 25mL of dichloromethane and to this solution add methanesulfonyl chloride (1.13g, 9.9mmol) and triethylamine (0.93g, 9.2mmol). Stir the reaction for 45 minutes, then extract the reaction mixture with water, brine, and then dry the organic layer over sodium sulfate. Concentrate the solution to yield the title compound (1.62g, 94% yield) as a yellow oil.

Step c: (1R,3S)-Cis-1-(9-adenyl)-3-(2-tetrahydropyranloxy)-4-cyclopentene

10 [0037] Add sodium hydride (80%, 0.57g, 19.8mmol) to a stirring suspension of adenine (2.67g, 19.8mmol) in 100mL of DMF at 60°C. After stirring for 3 hours at 60°C, add (1R,4S)-Cis-1-methanesulfonyloxy-4-(2-tetrahydropyranloxy)-2-cyclopentene (1.62g, 6.2mmol) and continue stirring at 60°C for 1 hour. Cool the reaction mixture to room temperature and stir overnight. The next day, heat the reaction mixture to 60°C for 6 hours and then allow to cool to room temperature overnight. Remove the DMF under vacuum and take the residue up in stirring dichloromethane and water. Remove the organic layer, extract it with brine and then dry it over sodium sulfate. Remove the solvent under vacuum and dissolve the residue in dichloromethane. Apply the solution to a silica gel column (10g) eluting with dichloromethane/ethanol (19:1) to yield the title compound (500mg, 26.7% yield).

20 Step d: (1R,3S)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentene hydrochloride

25 [0038] Dissolve (1R,3S)-Cis-1-(9-adenyl)-3-(2-tetrahydropyranloxy)-4-cyclopentene (0.5g, 1.7mmol) in 50mL of distilled water and 1.5mL of 6N hydrochloric acid. Stir the mixture for 12 hours at room temperature and then concentrate to dryness under vacuum. Take the residue up in ethanol with enough ammonium hydroxide to effect a solution, and then add an equal volume of dichloromethane (ammonium chloride precipitates). Apply the mixture to a silica gel column (50g, 70-230 mesh) eluting with dichloromethane/methanol (4:1) and recovering the title compound in 40mL fractions. Combine and concentrate the fractions containing pure material to dryness. Dissolve the residue in ethanol and add enough 6N HCl to adjust the pH to 1. Concentrate the solution to dryness to yield the title compound (230mg, 62% yield).

30 Step e: (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentane hydrochloride

35 [0039] Dissolve (1R,3S)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentene hydrochloride (230mg, 0.99mmol) in 25mL methanol and 75mL of distilled water. Add platinum (IV) oxide (50mg) and hydrogenate the mixture under 2.069 bar (30 psi) of hydrogen for 3.5 hours. Filter the mixture through a pad of celite and concentrate the filtrate to dryness. Dissolve the product in methanol, apply the solution to 20g of silica gel and elute with dichloromethane:methanol (9:1). Concentrate the fractions containing product to dryness and dissolve the residue in methanol. Adjust the pH to 1 with 6N HCl.

40 Concentrate this material to dryness to give the title compound (210mg, 83% yield).

[ $\alpha$ ]<sub>365</sub>=+24.4° (methanol, 1.0 mg/mL).

H<sup>1</sup>-NMR(DMSO/TMS) δ = 8.7(s, 1H), 8.5(s, 1H), 5.02(m, 1H), 4.3(m, 1H), 2.4-1.8(m, 6H).


45 [0040] The following compounds can be prepared by procedures analogous to those described above for Example 1 using readily available starting materials:

(1S,3R)-Cis-1-[9-(3-deazaadenyl)]-3-hydroxycyclopentane hydrochloride  
 (1S,3R)-Cis-1-[9-(7-deazaadenyl)]-3-hydroxycyclopentane hydrochloride  
 (1S,3R)-Cis-1-[9-purinyl]-3-hydroxycyclopentane hydrochloride  
 (1S,3R)-Cis-1-[9-(8-azaadenyl)]-3-hydroxycyclopentane hydrochloride  
 (1S,3R)-Cis-1-[9-(2-aminopurinyl)]-3-hydroxycyclopentane hydrochloride  
 (1S,3R)-Cis-1-[9-(2,6-diaminopurinyl)]-3-hydroxycyclopentane hydrochloride  
 (1S,3R)-Cis-1-[9-(2-amino-6-chloropurinyl)]-3-hydroxycyclopentane hydrochloride.

50 [0041] The starting materials for the synthetic scheme described above, including (1R, 4S)-Cis-1-acetoxy-2-cyclopenten-4-ol, adenine, 7-deazaadenine, purine, 8-azaadenine, 2-aminopurine, 2,6-diaminopurine and 2-amino-6-chloropurine, are readily available or can be made according to conventional procedures and techniques well known and appreciated in the art.

55 [0042] A general synthetic procedure for preparing compounds of formula (1) wherein Y<sub>8</sub> and Y<sub>9</sub> are each a CH group is set forth in Scheme B.

Scheme B



[0043] In step a, the 2-cyclopentene derivative (4) is reacted with the sodium anion of methyl methylsulfinylmethyl sulfide to yield the corresponding 1-substituted derivative (7).

[0044] In step b, the sodium anion of (7) is reacted with the appropriate pyrimidine or pyridine derivative, such as 5-amino-4,6-dichloropyrimidine, followed by hydrolysis to give the corresponding ketone derivative (8).

[0045] In step c, the ketone derivative (8) is converted to the corresponding enol ether (9) by reacting (8) with the appropriate Wittig reagent, such as  $\phi_3P=CH_2OCH_3$  [methoxymethyl triphenylphosphonium chloride], in the presence of *n*-butyllithium.

[0046] In step d, the enolate (9) is cyclized in the presence of acid, such as HCl, and the 3-hydroxy blocking group is removed according to standard techniques well known and appreciated in the art, to give the 6-substituted carbocyclic nucleoside analog (10).

[0047] In step e, the 6-substituted carbocyclic nucleoside analog (10) is hydrogenated as described in Scheme A, step e, to yield the 6-substituted nucleoside derivative (1b). Where the 6-substituted carbocyclic nucleoside analog

(10) bears a chlorine in the 6-position, the 6-chloro derivative can be converted to the 6-amino or 6-hydrogen derivative according to standard techniques well known and appreciated in the art.

[0048] The following example presents a typical synthesis as described by Scheme B. This example is understood to be illustrative only.

5

### EXAMPLE 2

#### (1S,3R)-Cis-1-[9-(9-deazaadenyl)]3-hydroxycyclopentane hydrochloride

10

#### Step a: (1R,4S)-Cis-4-t-butyldimethylsilyloxy-1-[methyl(1-methylsulfinyl-1-methylsulfide)]-2-cyclopentene

15

[0049] To a stirring solution of methyl methylsulfinylmethyl sulfide (1.2 equivalents) in THF at 0°C add n-butyl lithium (1.2 equivalents) and allow to stir for 15 minutes. Over a 15 minute period, add dropwise a solution of (1R,4S)-Cis-1-methanesulfonyloxy-4-t-butyldimethylsilyloxy-2-cyclopentene (1 equivalent) in THF and allow to stir for several hours at 0°C to 25°C. Dilute the reaction with water and extract with ethyl acetate or methylene chloride. Wash the organic layer with water, brine, and dry over sodium sulfate. Concentrate the solution to dryness to yield the title compound as a crude product.

20

#### Step b: (1R,4S)-Cis-4-t-butyldimethylsilyloxy-1-[carbonyl(4-[5-amino-6-chloropyrimidine])]2-cyclopentene

25

[0050] To a stirring solution of (1R,4S)-Cis-4-t-butyldimethylsilyloxy-1-[methyl(1-methylsulfinyl-1-methylsulfide)]-2-cyclopentene (1 equivalent) in THF at 0°C add n-butyllithium and continue stirring for 15 minutes. Over a 15 minute period, add dropwise a solution of 5-amino-4,6-dichloropyrimidine (1.1 equivalents) in THF and stir the reaction mixture for 24 hours at room temperature. Dilute the reaction with water and extract with ethyl acetate or methylene chloride. Wash the organic layer with water, brine, and dry over sodium sulfate. Concentrate the solution to dryness to yield the title compound as a crude product. Purify the title compound using a silica gel column eluting with ethyl acetate/hexane.

30

#### Step c: (1R,4S)-Cis-4-t-butyldimethylsilyloxy-1-[ethylene-1-(4-[5-amino-6-chloropyrimidine])-2-methoxy]-2-cyclopentene

35

[0051] To a stirring suspension of methoxymethyl triphenylphosphylidine chloride (1.2 equivalents) in THF at 0°C add n-butyllithium (1.2 equivalents) followed by stirring for 1 hour. Over a 15 minute period, add (1R,4S)-Cis-4-t-butyldimethylsilyloxy-1-[carbonyl(4-[5-amino-6-chloropyrimidine])]2-cyclopentene (1 equivalent) in THF and stir overnight at 0°C. Concentrate the reaction mixture to dryness and dissolve the residue in diethyl ether. Cool to 0°C for 1 hour and remove the precipitate (lithium chloride and triphenylphosphineoxide) by filtration. Concentrate the filtrate to yield the title compound. Purify the title compound using a silica gel column eluting with ethyl acetate/hexane.

#### Step d: (1R,3S)-Cis-1-[9-(9-deazaadenyl)]-3-hydroxy-4-cyclopentene Hydrochloride

40

[0052] Dissolve (1R,4S)-Cis-4-t-butyldimethylsilyloxy-1-[ethylene-1-(4-[5-amino-6-chloropyrimidine])-2-methoxy]-2-cyclopentene in aqueous methanol and a sufficient amount of 6 N HCl and stir at room temperature for 4 hours. Neutralize the product with ammonium hydroxide and concentrate the reaction mixture to dryness to yield (1R,3S)-Cis-3-t-butyldimethylsilyloxy-1-[9-(6-chloro-9-deazapurinyl)]-4-cyclopentene. Purify the product using a silica gel column eluting with methylene chloride/ethanol.

45

[0053] Enclose (1R,3S)-Cis-3-t-butyldimethylsilyloxy-1-[9-(6-chloro-9-deazapurinyl)]-4-cyclopentene in a sealed container of methanol and anhydrous ammonia for 24 hours applying heat if necessary. Remove the solvent and apply the product to a Dowex 50W™ column eluting with dilute ammonium hydroxide. Concentrate the eluant to dryness, take up in water, make acidic with 6 N HCl and stir for 4 hours. Concentrate the solution to dryness to yield the title compound.

50


#### Step e: (1S,3R)-Cis-1-[9-(9-deazaadenyl)]-3-hydroxycyclopentane Hydrochloride

55

[0054] Dissolve (1R,3S)-Cis-1-[9-(9-deazaadenyl)]-3-hydroxy-4-cyclopentene Hydrochloride in ethanol/water (1:1) and add platinum oxide. React in a Parr hydrogenator charged with 2,414 bar (35 psi) of hydrogen for 12 hours. Remove the catalyst by filtration and concentrate the filtrate to dryness to yield the title compound.

[0055] A general synthetic procedure for preparing compounds of formula (1) wherein Y<sub>9</sub> is a CH group and Y<sub>8</sub> is a nitrogen is set forth in Scheme C.

Scheme C



[0056] In step a, the ketone derivative (8), made as described in Scheme B, is converted to the corresponding oxime derivative and then cyclized to the corresponding 8-aza-9-deaza-6-substituted-nucleoside derivative (11) by reacting the oxime with diethylazodicarboxylate (DEAD) and triphenylphosphine. In addition, the 3-hydroxy blocking group of (8) is removed according to standard techniques well known and appreciated in the art.

[0057] In step b, the 8-aza-9-deaza-6-substituted-nucleoside derivative (11) can be converted to the corresponding 8-aza-9-deaza-6-substituted-carbocyclic adenosine derivative (1c) by hydrogenation as described in Scheme A, step e. Where the 8-aza-9-deaza-6-substituted-carbocyclic adenosine derivative (1c) bears a chlorine in the 6-position; the 6-chloro derivative can be converted to the 6-amino or 6-hydrogen derivative according to standard techniques well known and appreciated in the art.

30 EXAMPLE 3

**(1S,3R)-Cis-1-[9-(8-aza-9-deazaadenyl)]3-hydroxycyclopentane hydrochloride**

**Step a: (1*R*,3*S*)-Cis-1-[9-(8-aza-9-deazaadenyl)]-3-hydroxy-4-cyclopentene Hydrochloride**

[0058] To a solution of (1R;4S))-cis-4-t-butylidimethylsilyloxy-1-[carbonyl(4-[5-amino-6-chloropyrimidine])-2-cyclopentene (1 equivalent) and hydroxylamine hydrochloride (1.2 equivalents) in dry methanol add a solution of sodium hydroxide (1.2 equivalents). After 2 hours add water and collect and dry the solid thus formed (oxime intermediate). Dissolve the oxime intermediate (1 equivalent) in methylene chloride followed by DEAD (1.2 equivalents) and triphenylphosphine (1.1 equivalents). Allow the mixture to react for 2 hours to yield (1R,3S)-Cis-3-t-butylidimethylsilyloxy-1-(9-[8-aza-6-chloro-9-deazapurinyl])-4-cyclopentene. Extract the reaction mixture with water and then brine. Dry the organic layer over sodium sulfate, concentrate to dryness and add diethyl ether to precipitate out the triphenylphosphine oxide. Remove the precipitate by filtration and purify the product on a silica gel column eluting with ethyl acetate/hexane. Enclose (1R,3S)-Cis-3-t-butylidimethylsilyloxy-1-(9-[8-aza-6-chloro-9-deazapurinyl])-4-cyclopentene in a sealed container of methanol and anhydrous ammonia for 24 hours applying heat if necessary. Remove the solvent and apply the product to a Dowex 50W column eluting with dilute ammonium hydroxide. Concentrate the eluant to dryness, take up in water, make acidic with 6 N HCl and stir for 4 hours. Concentrate the solution to dryness to yield the Title compound.

50 Step b: (1S,3R)-Cis-1-[9-(8-aza-9-deazaadenyl)]-3-hydroxycyclopentane Hydrochloride


[0059] Dissolve (1*R*,3*S*)-*Cis*-1-[9-(8-aza-9-deazaadenyl)]-3-hydroxy-4-cyclopentene Hydrochloride in ethanol/water (1:1) and add platinum oxide. React in a Parr hydrogenator charged with 2,414 bar (35 psi) of hydrogen for 12 hours. Remove the catalyst by filtration and concentrate the filtrate to dryness to yield the title compound.

55 [0060] In general, where it is desired to synthesize the corresponding (1R,3S) enantiomer of the compounds of formula (1), procedures similar to those described above may be followed, except that instead of blocking the 4-hydroxy group of the intermediate (2) (so that a leaving group may be attached to the 1-position after hydrolysis of the acetoxy group), an appropriate leaving group is attached at the 4-position leaving the 1-acetoxy group or other appropriate

blocking group at the 1-position.

[0061] For example, a general synthetic procedure for preparing the corresponding (1R,3S) enantiomers of the compounds of formula (1) wherein Y<sub>9</sub> is nitrogen is set forth in Scheme D.

5



30

35

40

45

**L = Leaving group**

[0062] In step a, the 4-hydroxy moiety of (1R,4S)-Cis-1-acetoxy-2-cyclopenten-4-ol (2) is derivatized with a suitable leaving group (L), by procedures as described in Scheme A, to form the corresponding 2-cyclopentene derivative (4a).

50 Representative examples of suitable leaving groups are triflate, brosyl, tosyl, methanesulfonyl and the like. The preferred leaving group is a methanesulfonyl group.

[0063] In step b, the 2-cyclopentene derivative (4a) bearing a leaving group in the 4-position and an acetoxy group in the 1-position, is subjected to a displacement by the desired nucleoside base (wherein Y<sub>9</sub> is nitrogen) to give the corresponding 1-acetoxy-carbocyclic nucleoside analog (5a) with retention of configuration. This reaction may be carried out as described for the displacement reaction in Scheme A.

[0064] In step c, the 1-acetoxy group of the 1-acetoxy-carbocyclic nucleoside analog (5a) is removed according to standard procedures and techniques well known and appreciated in the art to give the corresponding unsaturated carbocyclic nucleoside analog (6a). For example, the 1-acetoxy group can be removed by treatment with base, such

as potassium carbonate.

[0065] In step d, the unsaturated carbocyclic nucleoside analog (6a) is hydrogenated according to standard procedures and techniques well known and appreciated in the art to give the corresponding carbocyclic nucleoside analog (Id).

5 [0066] The following example presents a typical synthesis as described by Scheme D. This example is understood to be illustrative only and is not intended to limit the scope of the invention in any way.

#### EXAMPLE 4

10 (1R,3S)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentane hydrochloride

##### Step a: (1S,4R)-Cis-1-methanesulfonyloxy-4-acetoxy-2-cyclopentene

15 [0067] Dissolve (1R,4S)-Cis-1-acetoxy-2-cyclopenten-4-ol (1.42g, 10.0mmol) in 40mL of dichloromethane. To this solution, add methanesulfonyl chloride (3.72g, 30.0mmol) and triethylamine (3.63g, 30.0mmol) and allow to stir for 4.5 hours. Extract the mixture sequentially with water and then brine. Dry the organic layer over sodium sulfate. Concentrate the solution to yield the title compound as a yellow oil (2.09g, 95% yield) which is used immediately in the next reation.

##### Step b: (1S,3R)-Cis-1-(9-adenyl)-3-acetoxy-4-cyclopentene

20 [0068] To a stirring suspension of adenine (4.1g, 30.0mmol) in 50mL of dimethylformamide at 60°C, add sodium hydride (60%, 1.0g, 30.0mmol). After the solution has stirred for 3 hours at 60°C, add (1S,4R)-Cis-1-methanesulfonyloxy-4-acetoxy-2-cyclopentene (2.09g, 9.5mmol) and continue stirring at 60°C for 16 hours. Remove the dimethylformamide under vacuum and take the residue up in stirring dichloromethane and water. Remove the organic layer, extract 25 with brine and dry the organic layer over sodium sulfate. Remove the solvent under vacuum and dissolve the residue in dichloromethane. Apply the solution to a silica gel column (40g) and elute with chloroform/methanol (9:1) to yield the title compound (1.07g) (33% yield).

##### Step c: (1S,3R)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentene

30 [0069] Dissolve (1S,3R)-Cis-1-(9-adenyl)-3-acetoxy-4-cyclopentene (0.5g, 1.7mmol) in 25mL of methanol, then add 3mL water and then 600mg K<sub>2</sub>CO<sub>3</sub>. Stir the mixture for 1 hour at room temperature, and then concentrate the mixture to dryness under vacuum. Take up the solid in ethanol to precipitate K<sub>2</sub>CO<sub>3</sub> and filter the mixture. Add an equal amount of dichloromethane. Apply the mixture to a silica gel column (50g, 70-230 mesh) and elute with dichloromethane/methanol (4:1). Collect fractions (40mL) and concentrate the fractions containing pure material to dryness to yield the title compound (257mg, 62% yield).

##### Step d: (1R,3S)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentane hydrochloride

40 [0070] Dissolve (1S,3R)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentene (50mg, 0.2mmol) in 5 mL ethanol and 15 mL distilled water. To this solution add 50mg of platinum (IV) oxide and hydrogenate the mixture under 2,069 bar (30 psi) of hydrogen gas for 3.5 hours. Filter the mixture through a pad of celite and concentrate the filtrate to dryness to yield the title compound (41mg, 82% yield).

[ $\alpha$ ]<sub>365</sub> = -24° (MeOH, 0.29mg/mL)

45 H<sup>1</sup>-NMR(DMSO/TMS)  $\delta$  = 8.7(s,1H), 8.5(s,1H), 5.02(m,1H), 4.3(m,1H), 2.4-1.8(m,6H).

[0071] The present invention further provides pharmaceutical compositions useful in effecting immunosuppression, and more specifically, in suppressing adaptive immunity, comprising an effective immunosuppressive amount of a compound of formula (1).

50 [0072] As used herein, the term "patient" refers to a warm-blooded animal such as a mammal which is suffering from a disease, such as an autoimmune disease or "graft versus host" disease, or is in danger of rejection of a transplanted allogeneic tissue or organ. It is understood that humans, mice and rats are included within the scope of the term "patient".

55 [0073] Administration of a pharmaceutical composition containing a compound of formula (1) to a patient results in an immunosuppressive effect in the patient. More specifically, administration of a pharmaceutical composition containing a compound of formula (1) to a patient results in suppression of adaptive immunity in the patient. In other words, by treatment of a patient with a pharmaceutical composition containing a compound of formula (1), the adaptive immune response of the patient is inhibited or suppressed over that present in the absence of treatment.

[0074] A patient is in need of treatment with an immunosuppressive composition, such as a pharmaceutical compo-

sition containing a compound of formula (1), where the patient is suffering from an autoimmune disease, "graft versus host" disease or in order to prevent rejection of transplanted allogeneic tissues or organs. The term "autoimmune disease" refers to those disease states and conditions wherein the immune response of the patient is directed against the patient's own constituents resulting in an undesirable and often terribly debilitating condition.

5 [0075] Patients suffering from autoimmune diseases such as rheumatoid arthritis, insulin-dependent diabetes mellitus, certain hemolytic anemias, rheumatic fever, thyroiditis, ulcerative colitis, myestheniagravis, glomerulonephritis, allergic encephalo-myelitis, continuing nerve and liver destruction which sometimes follows viral hepatitis, multiple sclerosis and systemic lupus erythematosus are in need of treatment with an immunosuppressive agent such as a compound of formula (1). Rheumatoid arthritis, insulin-dependent diabetes mellitus and multiple sclerosis are characterized as being the result of a cell-mediated autoimmune response and appear to be due to the action of T-cells. Myestheniagravis and systemic lupus erythematosus are characterized as being the result of a humoral autoimmune response. As such, administration of a pharmaceutical composition comprising a compound of formula (1) will be particularly effective in preventing further deterioration or worsening of a patient's condition suffering from these diseases. Administration of a pharmaceutical composition comprising a compound of formula (1) to a patient at an early 10 stage of an autoimmune disease, such as rheumatoid arthritis, insulin-dependent diabetes mellitus, multiple sclerosis, myestheniagravis or systemic lupus erythematosus, would be particularly effective in preventing further deterioration of the disease state into a more serious condition. For example, insulin-dependent diabetes mellitus (IDDM) is an autoimmune disease which is believed to result from the autoimmune response directed against the  $\beta$ -cells of the islets of Langerhans which secrete insulin. Administration of a pharmaceutical composition comprising a compound of formula (1) to a patient suffering from an early stage of IDDM prior to the complete destruction of the  $\beta$ -cells of the islets of Langerhans would be particularly useful in preventing further progression of the disease since it would prevent or 15 inhibit further destruction of remaining insulin-secreting  $\beta$ -cells. It is understood that administration of a pharmaceutical composition comprising a compound of formula (1) to a patient suffering from an early stage of other autoimmune diseases will also be particularly useful to prevent or inhibit further natural progression of the disease state to more 20 serious stages.

25 [0076] Patients who have received or who are about to receive an allogeneic tissue or organ transplant, such as an allogeneic kidney, liver, heart, skin, bone marrow, are also patients who are in need of prophylactic treatment with an immunosuppressive agent such as a compound of formula (1). An immunosuppressive agent will prevent the adaptive immune response of the donee from rejecting the allogeneic tissue or organ of the donor. Likewise, patients suffering 30 from "graft versus host" disease are patients who are in need of treatment with an immunosuppressive agent such as a compound of formula (1). An immunosuppressive agent will prevent the adaptive immune response of the transplanted tissue or organ from rejecting the allogeneic tissue or organ of the donee.

35 [0077] Based on standard clinical and laboratory tests and procedures, an attending diagnostician, as a person skilled in the art, can readily identify those patients who are in need of treatment with an immunosuppressive agent such as a compound of formula (1).

40 [0078] An effective immunosuppressive amount of a compound of formula (1) is that amount which is effective, upon single or multiple dose administration to a patient, in providing an immunosuppressive effect or, more particularly, a suppression of adaptive immune response. An immunosuppressive effect refers to the slowing, interrupting, inhibiting or preventing the further expression of the adaptive immune response.

45 [0079] An effective immunosuppressive amount of a compound of formula (1) can be readily determined by the attending diagnostician, as one skilled in the art, by the use of known techniques and by observing results obtained under analogous circumstances. In determining the effective amount or dose, a number of factors are considered by the attending diagnostician, including, but not limited to: the species of mammal; its size, age, and general health; the specific disease involved; the degree of or involvement or the severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; the bioavailability characteristics of the preparation administered; the dose regimen selected; the use of concomitant medication; and other relevant circumstances.

50 [0080] An effective immunosuppressive amount of a compound of formula (1) is expected to vary from about 0.1 milligram per kilogram of body weight per day (mg/kg/day) to about 500 mg/kg/day. Preferred amounts are expected to vary from about 1 to about 50 mg/kg/day.

55 [0081] Pharmaceutical compositions containing a compound of formula (1) can be administered in any form or mode which makes the compound bioavailable in effective amounts, including oral and parenteral routes. For example, they can be administered orally, subcutaneously, intramuscularly, intravenously, transdermally, intranasally, rectally, and the like. Oral administration is generally preferred. One skilled in the art of preparing formulations can readily select the proper form and mode of administration depending upon the particular characteristics of the compound selected the disease state to be treated, the stage of the disease, and other relevant circumstances.

[0082] The pharmaceutical composition can be administered alone or in the form of a pharmaceutical composition in combination with pharmaceutically acceptable carriers or excipients, the proportion and nature of which are deter-

mined by the solubility and chemical properties of the compound selected, the chosen route of administration, and standard pharmaceutical practice. The compounds of the invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like..

5 [0083] In another embodiment, the present invention provides compositions comprising a compound of formula (1) in admixture or otherwise in association with one or more inert carriers. These compositions are useful, for example, as assay standards, as convenient means of making bulk shipments, or as pharmaceutical compositions. An assayable amount of a compound of formula (1) is an amount which is readily measurable by standard assay procedures and techniques as are well known and appreciated by those skilled in the art. Assayable amounts of a compound of formula 10 (1) will generally vary from about 0.001% to about 75% of the composition by weight. Inert carriers can be any material which does not degrade or otherwise covalently react with a compound of formula (1). Examples of suitable inert carriers are water; aqueous buffers, such as those which are generally useful in High Performance Liquid Chromatography (HPLC) analysis; organic solvents, such as acetonitrile, ethyl acetate, hexane and the like; and pharmaceutically acceptable carriers or excipients.

15 [0084] More particularly, the present invention provides pharmaceutical compositions comprising an effective immunosuppressive amount of a compound of formula (1) in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

[0085] The pharmaceutical compositions are prepared in a manner well known in the pharmaceutical art. The carrier or excipient may be a solid, semi-solid, or liquid material which can serve as a vehicle or medium for the active ingredient. Suitable carriers or excipients are well known in the art. The pharmaceutical composition may be adapted for 20 oral or parenteral use, including topical use, and may be administered to the patient in the form of tablets, capsules, suppositories, solution, suspensions, or the like.

25 [0086] The pharmaceutical compositions of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 4% of the compound of the invention, the active ingredient, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of the compound present in compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 5.0-300 30 milligrams of a compound of the invention.

[0087] The tablets, pills, capsules, troches and the like may also contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrating agents such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; 35 glidants such as colloidal silicon dioxide; and sweetening agents such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may 40 contain, in addition to the present compounds, sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.

[0088] For the purpose of parenteral therapeutic administration, including topical administration, the compounds of 45 the present invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of a compound of the invention, but may be varied to be between 0.1 and about 50% of the weight thereof. The amount of the inventive compound present in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 5.0 to 100 milligrams of the compound of the invention.

[0089] The solutions or suspensions may also include the one or more of the following adjuvants: sterile diluents 50 such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.

[0090] As with any group of structurally related compounds which possesses a particular generic utility, certain groups 55 and configurations are preferred for compounds of formula (1) in their end-use application. Compounds of the formula (1) wherein  $Y_3$  is nitrogen are generally preferred. Compounds of the formula (1) wherein  $Y_7$  is nitrogen are generally preferred. Compounds of the formula (1) wherein  $Y_8$  is a CH group are generally preferred.

Compounds of the formula (1) wherein  $Y_9$  is nitrogen are generally preferred. Furthermore, compounds of the formula (1) wherein Q is  $\text{NH}_2$  and Z is hydrogen are generally preferred.

[0091] The following specific compounds of formula (1) are especially preferred:

5 (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentane hydrochloride  
 (1R,3S)-Cis-1-(9-adenyl)-3-hydroxycyclopentane hydrochloride.

[0092] The following studies illustrate the utility of the compounds of formula (1). These studies are understood to be illustrative only and are not intended to limit the scope of the invention in any way. As used herein the following 10 terms have the indicated meanings: " $\mu\text{M}$ " refers to micromolar concentration; "Units" refers to the internationally accepted measurement of protein; "S.D." refers to standard deviation; " $\eta\text{mol}$ " refers to nanomoles; " $\eta\text{g}$ " refers to nanograms.

[0093] Rat peritoneal macrophages were isolated and grown in cell culture essentially as described by Edwards et al. [*Science* 239, 769 (1988)]. Macrophages were incubated along with opsonized zymosan (3 mg/mL), which acts as a particulate stimulus, and recombinant rat  $\gamma$ -interferon (rrIFN- $\gamma$ )(1000Units/mL), which acts as an activating lymphokine, in the presence of various concentrations of (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentane (0 to 1000 $\mu\text{M}$ ). The degree of macrophage priming was measured using the Superoxide Anion ( $\text{O}_2^-$ ) assay as described by Edwards et al. [*Science* 239, 769 (1988)]. The results of this study show that (1S,3R)-Cis-1-(9-adenyl)-3-hydroxy-4-cyclopentene effectively inhibits the priming of rat macrophages *in vitro* with an  $IC_{50}$  of 2.5  $\mu\text{M}$ .

[0094] The rat air pouch model of inflammation was used to obtain rat PMNs using 25 $\eta\text{g}/\text{pouch}$  of recombinant 15 human interleukin-1 (rHuIL-1) to elicit the cells essentially according to the method of Esser et al. [*Internat. J. Tissue Reactions* XI, 291 (1989)]. PMNs were incubated along with phorbol myristate acetate (PMA)(200 $\eta\text{g}/\text{mL}$ ), which acts as a soluble stimulus, and rrIFN- $\gamma$ (1000 Units/mL), which acts as a stimulatory lymphokine, or rHuIL-1 (500 Units/mL), which acts as a stimulatory cytokine, in the presence of various concentrations of (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentane (0 to 1000  $\mu\text{M}$ ). The degree of macrophage priming was measured using the Superoxide Anion ( $\text{O}_2^-$ ) assay as described by Edwards et al. [*Science* 239, 769 (1988)]. The results of this study show that (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentane effectively inhibits the rrIFN- $\gamma$  priming of rat PMN *in vitro* with an  $IC_{50}$  of 0.001  $\mu\text{M}$  and effectively inhibits the rHuIL-1 priming of rat PMN *in vitro* with an  $IC_{50}$  of 0.001 $\mu\text{M}$ .

30

### Claims

Claims for the following Contracting States : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE


35

1. A compound of the formula (1)

40

45

50



wherein

55 the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,  $Y_3$ ,  $Y_7$ ,  $Y_8$  and  $Y_9$  are each independently nitrogen or a CH group.


Q is  $\text{NH}_2$ , halogen or hydrogen, and  
 Z is hydrogen, halogen, or  $\text{NH}_2$ ;

or a pharmaceutically-acceptable salt thereof.

2. A compound of Claim 1 wherein the compound is (1S,3R)-Cis-1(9-adenyl)-3-hydroxycyclopentane.
- 5 3. A compound of Claim 1 wherein the compound is (1R,3S)-Cis-1(9-adenyl)-3-hydroxycyclopentane.
4. A composition comprising an assayable amount of a compound of any of Claims 1 to 3 in admixture or otherwise in association with an inert carrier.
- 10 5. A pharmaceutical composition comprising an effective immunosuppressive amount of a compound of any of Claims 1 to 3 in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.
6. A pharmaceutical composition according to Claim 5 useful in effecting immunosuppression.
- 15 7. A pharmaceutical composition according to Claim 5 useful in suppressing adaptive immunity.
8. A pharmaceutical composition according to Claim 5 useful in the treatment for allograft rejection.
9. A pharmaceutical composition according to Claim 5 useful in the treatment for an autoimmune disease.
- 20 10. A pharmaceutical composition according to Claim 9 wherein the autoimmune disease is insulin-dependent diabetes mellitus.
11. A pharmaceutical composition according to Claim 9 wherein the autoimmune disease is multiple sclerosis.
- 25 12. A pharmaceutical composition according to Claim 9 wherein the autoimmune disease is rheumatoid arthritis.
13. A pharmaceutical composition according to Claim 9 wherein the autoimmune disease is myasthenia gravis.
- 30 14. A pharmaceutical composition according to Claim 9 wherein the autoimmune disease is systemic lupus erythematosus.

**Claims for the following Contracting State : ES**

- 35 1. A process for making a compound of the formula (1)



wherein

55 the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,  
 Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> and Y<sub>9</sub> are each independently nitrogen or a CH group.

Q is NH<sub>2</sub>, halogen or hydrogen, and  
 Z is hydrogen, halogen, or NH<sub>2</sub>;

or a pharmaceutically-acceptable salt thereof, comprising subjecting the corresponding cyclopentenyl derivative to catalytic hydrogenation.

2. A process according to Claim 1 wherein the catalytic hydrogenation is carried out in the presence of PtO<sub>2</sub>.

5 3. A process according to Claim 1 wherein the compound prepared is (1S,3R)-Cis-1(9-adenyl)-3-hydroxycyclopentane.

10 4. A process according to Claim 1 wherein the compound prepared is (1R,3S)-Cis-1(9-adenyl)-3-hydroxycyclopentane.

5. A composition comprising an assayable amount of a compound prepared according to any of Claims 1 to 4 in admixture or otherwise in association with an inert carrier.

15 6. A method for the preparation of a pharmaceutical composition comprising combining an effective immunosuppressive amount of a compound prepared according to any of Claims 1 to 4 with one or more pharmaceutically acceptable carriers or excipients.

20 7. A method according to Claim 6 wherein the pharmaceutical composition prepared is useful in effecting immunosuppression.

8. A method according to Claim 6 wherein the pharmaceutical composition prepared is useful in suppressing adaptive immunity.

25 9. A method according to Claim 6 wherein the pharmaceutical composition prepared is useful in the treatment for allograft rejection.

10. A method according to Claim 6 wherein the pharmaceutical composition prepared is useful in the treatment for an autoimmune disease.

30 11. A method according to Claim 10 wherein the autoimmune disease is insulin-dependent diabetes mellitus.

12. A method according to Claim 10 wherein the autoimmune disease is multiple sclerosis.


35 13. A method according to Claim 10 wherein the autoimmune disease is rheumatoid arthritis.

14. A method according to Claim 10 wherein the autoimmune disease is myestheniagravis.

40 15. A method according to Claim 10 wherein the autoimmune disease is systemic lupus erythematosus.

**Claims for the following Contracting State : GR**

45 1. A compound of the formula (1)



wherein

the hydroxy substituent on the cyclopentanyl ring is in the CIS configuration relative to the bicyclic substituent,  
Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> and Y<sub>9</sub> are each independently nitrogen or a CH group,

5        Q    is NH<sub>2</sub>, halogen or hydrogen, and  
          Z    is hydrogen, halogen, or NH<sub>2</sub>;

10       or a pharmaceutically-acceptable salt thereof.

15       2. A compound of Claim 1 wherein the compound is (1S,3R)-Cis-1(9-adenyl)-3-hydroxycyclopentane.

20       3. A compound of Claim 1 wherein the compound is (1R,3S)-Cis-1(9-adenyl)-3-hydroxycyclopentane.

25       4. A composition comprising an assayable amount of a compound of any of Claims 1 to 3 in admixture or otherwise in association with an inert carrier.

30       5. Use of a compound of any of Claims 1 to 3 for the preparation of a pharmaceutical composition comprising an effective immunosuppressive amount of a compound of any of Claims 1 to 3 in admixture or otherwise in association with one or more pharmaceutically acceptable carriers or excipients.

35       6. Use according to Claim 5 wherein the pharmaceutical composition prepared is useful in effecting immunosuppression.

40       7. Use according to Claim 5 wherein the pharmaceutical composition is useful in suppressing adaptive immunity.

45       8. Use according to Claim 5 wherein the pharmaceutical composition is useful in the treatment for allograft rejection.

50       9. Use according to Claim 5 wherein the pharmaceutical composition is useful in the treatment for an autoimmune disease.

55       10. Use according to Claim 9 wherein the autoimmune disease is insulin-dependent diabetes mellitus.

60       11. Use according to Claim 9 wherein the autoimmune disease is multiple sclerosis.

65       12. Use according to Claim 9 wherein the autoimmune disease is rheumatoid arthritis.


70       13. Use according to Claim 9 wherein the autoimmune disease is myestheniagravis.

75       14. Use according to Claim 9 wherein the autoimmune disease is systemic lupus erythematosus.

### Patentansprüche

45       Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE

50       1. Verbindung der Formel (1)




## Patentansprüche für folgenden Vertragsstaat : ES

## 1. Verfahren zu Herstellung einer Verbindung der Formel (1)

5

10

15



in der

20 der Hydroxysubstituent an dem Cyclopentanylring relativ zu dem bicyclischen Substituenten in der CIS-Konfiguration vorliegt.

Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> und Y<sub>9</sub> jeweils unabhängig voneinander ein Stickstoffatom oder eine CH-Gruppe bedeuten,

25 Q NH<sub>2</sub>, ein Halogen- oder Wasserstoffatom darstellt und

Z ein Wasserstoff- oder Halogenatom oder NH<sub>2</sub> darstellt,

oder ein pharmazeutisch verträgliches Salz davon,

umfassend die Durchführung einer katalytischen Hydrierung mit dem entsprechenden Cyclopentenyllderivat.

30 2. Verfahren nach Anspruch 1, wobei die katalytische Hydrierung in Gegenwart von PtO<sub>2</sub> durchgeführt wird.

35 3. Verfahren nach Anspruch 1, wobei es sich bei der hergestellten Verbindung um (1S,3R)-Cis-1(9-adenyl)-3-hydroxycyclopentan handelt.

40 4. Verfahren nach Anspruch 1, wobei es sich bei der hergestellten Verbindung um (1R,3S)-Cis-1(9-adenyl)-3-hydroxycyclopentan handelt.

5. Zusammensetzung, umfassend eine bestimmbare Menge einer Verbindung nach einem der Ansprüche 1 bis 4 im Gemisch oder in anderer Verbindung mit einem Inerten Träger.

45 6. Verfahren zur Herstellung eines Arzneimittels, umfassend das Zusammenbringen einer wirksamen immunsuppressiven Menge einer Verbindung nach einem der Ansprüche 1 bis 4 mit einem oder mehreren pharmazeutisch verträglichen Trägern oder Excipienten.

7. Verfahren nach Anspruch 6, wobei das hergestellte Arzneimittel für das Bewirken von Immunsuppression geeignet ist.

8. Verfahren nach Anspruch 6, wobei das hergestellte Arzneimittel für die Unterdrückung der adaptiven Immunität geeignet ist.

50 9. Verfahren nach Anspruch 6, wobei das hergestellte Arzneimittel für die Behandlung von Allotransplantatabstößung geeignet ist.

10. Verfahren nach Anspruch 6, wobei das hergestellte Arzneimittel für die Behandlung einer Autoimmunerkrankung geeignet ist.

55 11. Verfahren nach Anspruch 10, wobei es sich bei der Autoimmunerkrankung um insulinabhängigen Diabetes mellitus handelt.

12. Verfahren nach Anspruch 10, wobei es sich bei der Autoimmunerkrankung um multiple Sklerose handelt.

13. Verfahren nach Anspruch 10, wobei es sich bei der Autoimmunerkrankung um rheumatoide Arthritis handelt.

5 14. Verfahren nach Anspruch 10, wobei es sich bei der Autoimmunerkrankung um Myasthenia gravis handelt.

15. Verfahren nach Anspruch 10, wobei es sich bei der Autoimmunerkrankung um systemischen Lupus erythematoses handelt.

10


## Patentansprüche für folgenden Vertragsstaat : GR

15 1. Verbindung der Formel (1)

15

20

25



30

in der  
 der Hydroxysubstituent an dem Cyclopentaniring relativ zu dem bicyclischen Substituenten in der CIS-Konfiguration vorliegt,  
 Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> und Y<sub>9</sub> jeweils unabhängig voneinander ein Stickstoffatom oder eine CH-Gruppe bedeuten,

35

Q NH<sub>2</sub>, ein Halogen- oder Wasserstoffatom darstellt und  
 Z ein Wasserstoff- oder Halogenatom oder NH<sub>2</sub> darstellt,

oder ein pharmazeutisch verträgliches Salz davon.

40

2. Verbindung nach Anspruch 1, wobei es sich bei der Verbindung um (1S,3R)-Cis-1-(9-adenyl)-3-hydroxycyclopentan handelt.

3. Verbindung nach Anspruch 1, wobei es sich bei der Verbindung um (1R,3S)-Cis-1-(9-adenyl)-3-hydroxycyclopentan handelt.

45 4. Zusammensetzung, umfassend eine bestimmbare Menge einer Verbindung nach einem der Ansprüche 1 bis 3 im Gemisch oder in anderer Verbindung mit einem inerten Träger.

5. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 3 zur Herstellung eines Arzneimittels, das eine wirksame immunsuppressive Menge einer Verbindung nach einem der Ansprüche 1 bis 3 im Gemisch oder in anderer Verbindung mit einem oder mehreren pharmazeutisch verträglichen Trägern oder Excipienten umfasst.

50 6. Verwendung nach Anspruch 5, wobei das hergestellte Arzneimittel für das Bewirken von Immunsuppression geeignet ist.

7. Verwendung nach Anspruch 5, wobei das Arzneimittel für die Unterdrückung der adaptiven Immunität geeignet ist.

55 8. Verwendung nach Anspruch 5, wobei das Arzneimittel für die Behandlung von Allotransplantatabstoßung geeignet

ist.

9. Verwendung nach Anspruch 5, wobei das Arzneimittel für die Behandlung einer Autoimmunerkrankung geeignet ist.
- 5 10. Verwendung nach Anspruch 9, wobei es sich bei der Autoimmunerkrankung um insulinabhängigen Diabetes mellitus handelt.
11. Verwendung nach Anspruch 9, wobei es sich bei der Autoimmunerkrankung um multiple Sklerose handelt.
- 10 12. Verwendung nach Anspruch 9, wobei es sich bei der Autoimmunerkrankung um rheumatoide Arthritis handelt.
13. Verwendung nach Anspruch 9, wobei es sich bei der Autoimmunerkrankung um Myasthenia gravis handelt.
- 15 14. Verwendung nach Anspruch 9, wobei es sich bei der Autoimmunerkrankung um systemischen Lupus erythematodes handelt.


#### Revendications

20

Revendications pour les Etats contractants suivants : AT, BE, CH, LI, DE, DK, FR, GB, IT, LU, NL, SE

1. Composé de formule (1) :

25



30

dans laquelle

le substituant hydroxy sur le cycle cyclopentanylique est en configuration CIS par rapport au substituant bicyclique,  
40 chacun de Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> et Y<sub>9</sub> est indépendamment l'azote ou un groupe CH,

45

Q est NH<sub>2</sub>, un halogène ou l'hydrogène, et

Z est l'hydrogène, un halogène ou NH<sub>2</sub> :

ou un sel acceptable en pharmacie d'un tel composé.

50

2. Composé selon la revendication 1, dans lequel le composé est le (1S,3R)-cis-1-(9-adényl)-3-hydroxycyclopentane.
3. Composé selon la revendication 1, dans lequel le composé est le (1R,3S)-cis-1-(9-adényl)-3-hydroxycyclopentane.
- 50 4. Composition comprenant une quantité dosable d'un composé selon l'une quelconque des revendications 1 à 3 en mélange ou en autre association avec un véhicule inerte.
5. Composition pharmaceutique comprenant une quantité immunodépressive efficace d'un composé selon l'une quelconque des revendications 1 à 3 en mélange ou en autre association avec un ou plusieurs véhicules ou excipients acceptables en pharmacie.
- 55 6. Composition pharmaceutique selon la revendication 5, utile pour effectuer une immunodépression.

7. Composition pharmaceutique selon la revendication 5, utile pour supprimer une immunité adaptative.

8. Composition pharmaceutique selon la revendication 5, utile dans le traitement d'un rejet d'allogreffe.

5 9. Composition pharmaceutique selon la revendication 5, utile dans le traitement d'une maladie auto-immune.

10. Composition pharmaceutique selon la revendication 9, dans laquelle la maladie auto-immune est le diabète sucré insulino-dépendant.

10 11. Composition pharmaceutique selon la revendication 9, dans laquelle la maladie auto-immune est la sclérose en plaques.


12. Composition pharmaceutique selon la revendication 9, dans laquelle la maladie auto-immune est la polyarthrite rhumatoïde.

15 13. Composition pharmaceutique selon la revendication 9, dans laquelle la maladie auto-immune est la myasthénie grave.

20 14. Composition pharmaceutique selon la revendication 9, dans laquelle la maladie auto-immune est le lupus érythémateux systémique.

**Revendications pour l'Etat contractant suivant : ES**

25 1. Procédé pour préparer un composé de formule (1) :



35 dans laquelle

le substituant hydroxy sur le cycle cyclopentanyle est en configuration CIS par rapport au substituant bicyclique,  
40 chacun de Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> et Y<sub>9</sub> est indépendamment l'azote ou un groupe CH,

45 Q est NH<sub>2</sub>, un halogène ou l'hydrogène, et  
Z est l'hydrogène, un halogène ou NH<sub>2</sub> ;  
ou un sel acceptable en pharmacie d'un tel composé,  
comportant le fait de soumettre le dérivé de cyclopentényle correspondant à une hydrogénéation cata-

50 2. Procédé selon la revendication 1, dans lequel l'hydrogénéation catalytique est mise en oeuvre en présence de PtO<sub>2</sub>.

3. Procédé selon la revendication 1, dans lequel le composé préparé est le (1S,3R)-cis-1-(9-adényl)-3-hydroxycyclopentane.

55 4. Procédé selon la revendication 1, dans lequel le composé préparé est le (1R,3S)-cis-1-(9-adényl)-3-hydroxycyclopentane.

5. Composition comprenant une quantité dosable d'un composé préparé selon l'une quelconque des revendications 1 à 4 en mélange ou en autre association avec un véhicule inerte.

6. Procédé pour la préparation d'une composition pharmaceutique comprenant la combinaison d'une quantité immunodépressive efficace d'un composé préparé selon l'une quelconque des revendications 1 à 4 avec un ou plusieurs véhicules ou excipients acceptables en pharmacie.

5 7. Procédé selon la revendication 6, dans lequel la composition pharmaceutique préparée est utile pour effectuer une immunodépression.

8. Procédé selon la revendication 6, dans lequel la composition pharmaceutique préparée est utile pour supprimer une immunité adaptative.

10 9. Procédé selon la revendication 6, dans lequel la composition pharmaceutique préparée est utile dans le traitement d'un rejet d'allograft.

15 10. Procédé selon la revendication 6, dans lequel la composition pharmaceutique préparée est utile dans le traitement d'une maladie auto-immune.

11. Procédé selon la revendication 10, dans lequel la maladie auto-immune est le diabète sucré insulino-dépendant.

12. Procédé selon la revendication 10, dans lequel la maladie auto-immune est la sclérose en plaques.


20 13. Procédé selon la revendication 10, dans lequel la maladie auto-immune est la polyarthrite rhumatoïde.

14. Procédé selon la revendication 10, dans lequel la maladie auto-immune est la myasthénie grave.

25 15. Procédé selon la revendication 10, dans lequel la maladie auto-immune est le lupus érythémateux systémique.

**Revendications pour l'Etat contractant suivant : GR**

30 1. Composé de formule (1) :



40 dans laquelle

le substituant hydroxy sur le cycle cyclopentanyle est en configuration CIS par rapport au substituant bicyclique,  
45 chacun de Y<sub>3</sub>, Y<sub>7</sub>, Y<sub>8</sub> et Y<sub>9</sub> est indépendamment l'azote ou un groupe CH,

Q est NH<sub>2</sub>, un halogène ou l'hydrogène, et  
Z est l'hydrogène, un halogène ou NH<sub>2</sub> ;

50 ou un sel acceptable en pharmacie d'un tel composé.

2. Composé selon la revendication 1, dans lequel le composé est le (1S,3R)-cis-1-(9-adényl)-3-hydroxycyclopentane.

3. Composé selon la revendication 1, dans lequel le composé est le (1R,3S)-cis-1-(9-adényl)-3-hydroxycyclopentane.

55 4. Composition comprenant une quantité dosable d'un composé selon l'une quelconque des revendications 1 à 3 en mélange ou en autre association avec un véhicule inerte.

5. Utilisation d'un composé selon l'une quelconque des revendications 1 à 3 pour la préparation d'une composition pharmaceutique comprenant une quantité immunodépressive efficace d'un composé selon l'une quelconque des revendications 1 à 3 en mélange ou en autre association avec un ou plusieurs véhicules ou excipients acceptables en pharmacie.
6. Utilisation selon la revendication 5, dans laquelle la composition pharmaceutique préparée est utile pour effectuer une immunodépression.
10. Utilisation selon la revendication 5, dans laquelle la composition pharmaceutique préparée est utile pour supprimer une immunité adaptative.
15. Utilisation selon la revendication 5, dans laquelle la composition pharmaceutique préparée est utile dans le traitement d'un rejet d'allograft.
9. Utilisation selon la revendication 5, dans laquelle la composition pharmaceutique préparée est utile dans le traitement d'une maladie auto-immune.
10. Utilisation selon la revendication 9, dans laquelle la maladie auto-immune est le diabète sucré insulino-dépendant.
20. 11. Utilisation selon la revendication 9, dans laquelle la maladie auto-immune est la sclérose en plaques.
12. Utilisation selon la revendication 9, dans laquelle la maladie auto-immune est la polyarthrite rhumatoïde.
13. Utilisation selon la revendication 9, dans laquelle la maladie auto-immune est la myasthénie grave.
25. 14. Utilisation selon la revendication 9, dans laquelle la maladie auto-immune est le lupus érythémateux systémique.

30

35

40

45

50

55